Overview

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Status:
Completed
Trial end date:
2018-01-26
Target enrollment:
Participant gender:
Summary
A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.
Phase:
Phase 1
Details
Lead Sponsor:
Seres Therapeutics, Inc.
Treatments:
Vancomycin